Sagimet Biosciences Inc.
SGMT
$2.21
$0.199.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -98.76% | -130.11% | -19.65% | -0.64% | -13.29% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.39% | -44.04% | -7.19% | -21.61% | 100.89% |
| Change in Net Operating Assets | 1,407.86% | -1,123.17% | 7,485.00% | 85.69% | 69.86% |
| Cash from Operations | -55.64% | -404.49% | 1.50% | 12.37% | 4.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 150.20% | -- | -687.16% | -84.54% | -460.93% |
| Cash from Investing | 150.20% | -- | -687.16% | -84.54% | -460.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -100.00% | 97.03% | -648.53% | -6,296.36% |
| Cash from Financing | -- | -100.00% | 97.03% | 77,192.65% | 100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.60% | -122.73% | -1,409.85% | 734.47% | -1,188.75% |